Exelixis Inc (EXEL) Valuation
Historical valuation analysis based on 500 data points (2024-09-24 to 2026-09-22)
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic m...
Exelixis Inc (EXEL) currently trades at a P/E ratio of 18.65 (historical range: 13.99–24.83, median: 18.14), placing it at the 64th percentile — above its historical average, P/S ratio of 6.54 (range: 3.62–6.65, 99th percentile — expensive relative to its history).
Over the historical period (2024-09-24 to 2026-09-22), Exelixis Inc's P/E ratio has contracted by 14% over the observed period (from an average of 20.1 to 17.2).
Exelixis Inc trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 18.65 | 13.99 | 18.14 | 24.83 | 64th | above its historical average |
| P/S Ratio | 6.54 | 3.62 | 5.20 | 6.65 | 99th | expensive relative to its history |
| FCF Yield | 0.06 | 0.04 | 0.06 | 0.08 | 29th | above its historical average |
Exelixis Inc (EXEL) Valuation & P/E History
Exelixis Inc (EXEL) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry currently trading at $58.15 with a market capitalization of $14.4 billion. This page provides historical valuation analysis for EXEL based on 500 data points covering 2024-09-24 to 2026-09-22. The P/E ratio of 18.65 is above the historical median of 18.14, placing EXEL at the 64th percentile of its valuation range. The P/S ratio of 6.54 compares to a median of 5.20.
EXEL Valuation Metrics & Historical Range
The valuation table above shows Exelixis Inc's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether EXEL is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests EXEL is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Exelixis Inc.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is EXEL Overvalued or Undervalued?
Exelixis Inc trades well above its own historical valuation range across most metrics. The overall valuation percentile of 82 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive EXEL is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full EXEL analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.EXEL trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.